• Hereditary angioedema (HAE) type I and II are bradykinin-mediated swellings of the skin and mucosal tissues characterised by debilitating, painful and potentially life-threatening acute attacks lasting 2-5 days ( Figure 1 ). [1] [2] [3] • HAE type I and II are linked to genetic defects in the SERPING1 gene, leading to a deficiency of C1-esterase inhibitor (C1-INH) protein. , CSL Behring).
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• These indirect comparison data were input into the model along with the following costs: drug cost; administration, monitoring and supportive care (taken from NHS reference costs 2009-2010); method and location of administration; number of attacks per year (to include the cost of vaccination and self-administration training); and requirement of hepatitis A and B vaccinations. These variables comprised the base-case scenario.
• Sensitivity analyses were performed to discover whether variations in any of the above values significantly impacted the cost-effectiveness comparisons.
• Quality-adjusted life years (QALYs) were estimated by combining data for the time-to-onset of symptom relief (the primary endpoint of the majority of relevant trials) and utility weights for two health states: during an attack (the period of time before the onset of symptom relief), and following recovery from the attack (after onset of symptom relief).
-Time-to-onset of symptom relief for icatibant-treated patients was estimated using a survival function and applying hazard ratios from the indirect comparison (Poster PSY10).
• A systematic review was performed to identify health-state utility value estimates relevant to the analysis. Two sources of data were identified (both unpublished):
-An Expert Panel scored quality-of-life for moderate and severe HAE attacks using the EQ-5D.
-Utility weights were estimated from visual analogue scale (VAS) scores observed in the FAST trials.
• In the cost-utility model, QALYs were estimated over the model time frame of 96 h (a duration that was estimated to include 99.9% of all moderate-to-severe attacks). 
RESULTS
Cost-effectiveness
• In the base-case analysis, the total costs per attack were estimated as £1,577 for icatibant and £2,169 for C1-INH (CSL Behring) 20 IU/kg ( Figure 3 ).
• This is equivalent to a saving of £592 (95% CI; £349-£715) per attack with icatibant (Table 1 ).
• The sensitivity analyses that affected these model results were:
In favour of icatibant -Increasing patient weight -Increasing proportion of patients who self-administer icatibant -Lower incidence of repeat icatibant dosing (at least 65% of patients using one icatibant syringe per attack)
In favour of C1-INH (CSL Behring) -C1-INH (CSL Behring) dose <20 IU/kg -Higher incidence of repeat icatibant dosing (fewer than 64% of patients using one icatibant syringe per attack)
QALYs
• The economic analysis demonstrated that the difference in QALYs between treatments was very small, and therefore not significant (Table 1 ).
• This difference was equivalent to approximately 0.75 quality-adjusted life hours, in favour of icatibant. 
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